Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NGFR | P08138 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813864 | 0.85 | CFTR (0.37) | PKMDHODHKDM4ECFTRALDH1A1 | |
| SCHEMBL30845399 | 0.85 | CFTR (0.37) | PKMDHODHKDM4ECFTRALDH1A1 | |
| SCHEMBL21813966 | 0.76 | KDM4E (0.52) | MAPTKDM4ECFTR | |
| SCHEMBL831077 | 0.76 | NOTUM (0.41) | NOTUMRBP4MRGPRX4MAPTKDM4E | |
| SCHEMBL21813977 | 0.72 | NGFR (0.54) | NGFRNOTUMNPC1PKMMAPT | |
| SCHEMBL31459158 | 0.72 | CFTR (0.41) | NOTUMRBP4MRGPRX4MAPTKDM4E | |
| SCHEMBL27274223 | 0.72 | CFTR (0.41) | NOTUMRBP4MRGPRX4MAPTKDM4E | |
| SCHEMBL2130395 | 0.68 | MAPT (0.42) | NOTUMMRGPRX4MAPTKDM4ECFTR | |
| SCHEMBL1327502 | 0.67 | GABRP (0.40) | NOTUMNPC1PKMMAPTKDM4E | |
| SCHEMBL30845442 | 0.66 | UGT8 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3861000-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | Genzyme Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072504-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | NGFR 3365/4885NOTUM 782/4885NPC1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.